Ovarian cancer is a complex disease, and for patients who respond to initial platinum-based chemotherapy, maintaining remission is a key treatment goal. Olaparib, a targeted PARP inhibitor, has revolutionized the approach to maintenance therapy for advanced and recurrent ovarian cancer, offering significant benefits, particularly for those with BRCA mutations or homologous recombination deficiency (HRD). The effectiveness of Olaparib in ovarian cancer treatment is rooted in its mechanism of action. By inhibiting PARP, it disrupts the DNA repair processes within cancer cells. In ovarian cancers with BRCA mutations or HRD, cells are already deficient in repairing DNA damage. Olaparib's action creates a synthetic lethal state, where the combined deficiencies lead to overwhelming DNA damage and cell death. This targeted approach is crucial for prolonging the period of remission and delaying disease progression. Clinical trials, such as SOLO-1 and PAOLA-1, have highlighted Olaparib's efficacy. For patients with newly diagnosed advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy, Olaparib as maintenance therapy has demonstrated a significant improvement in progression-free survival, especially when used in combination with bevacizumab for HRD-positive cases. Furthermore, Olaparib is indicated for the maintenance treatment of recurrent ovarian cancer patients in complete or partial response to platinum-based chemotherapy, regardless of BRCA status in some guidelines, underscoring its broad applicability. Access to high-quality Olaparib from trusted manufacturers is essential for its widespread use in clinical practice. As a leading supplier in China, we are committed to providing pharmaceutical-grade Olaparib that meets international standards, supporting advancements in ovarian cancer treatment and offering patients a more effective path forward. The consistent supply and competitive price of Olaparib make it an accessible option for many healthcare systems.